167 related articles for article (PubMed ID: 23503572)
1. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
2. Expression of the mTOR pathway regulators in human pituitary adenomas indicates the clinical course.
Jia W; Sanders AJ; Jia G; Liu X; Lu R; Jiang WG
Anticancer Res; 2013 Aug; 33(8):3123-31. PubMed ID: 23898069
[TBL] [Abstract][Full Text] [Related]
3. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
4. Guanine nucleotide binding protein β 1: a novel transduction protein with a possible role in human breast cancer.
Wazir U; Jiang WG; Sharma AK; Mokbel K
Cancer Genomics Proteomics; 2013; 10(2):69-73. PubMed ID: 23603342
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
6. PIH1D1 interacts with mTOR complex 1 and enhances ribosome RNA transcription.
Kamano Y; Saeki M; Egusa H; Kakihara Y; Houry WA; Yatani H; Kamisaki Y
FEBS Lett; 2013 Oct; 587(20):3303-8. PubMed ID: 24036451
[TBL] [Abstract][Full Text] [Related]
7. Distribution and association of mTOR with its cofactors, raptor and rictor, in cumulus cells and oocytes during meiotic maturation in mice.
Kogasaka Y; Hoshino Y; Hiradate Y; Tanemura K; Sato E
Mol Reprod Dev; 2013 Apr; 80(4):334-48. PubMed ID: 23440873
[TBL] [Abstract][Full Text] [Related]
8. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
[TBL] [Abstract][Full Text] [Related]
9. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
Jiang WG; Douglas-Jones AG; Mansel RE
Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
[TBL] [Abstract][Full Text] [Related]
11. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression.
Sticz T; Molnár A; Márk Á; Hajdu M; Nagy N; Végső G; Micsik T; Kopper L; Sebestyén A
J Clin Pathol; 2017 May; 70(5):410-416. PubMed ID: 27729429
[TBL] [Abstract][Full Text] [Related]
12. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways.
Zhang L; You J; Sidhu J; Tejpal N; Ganachari M; Skelton TS; Kloc M; Li XC; Ghobrial RM
Transplantation; 2013 Nov; 96(9):782-90. PubMed ID: 23985719
[TBL] [Abstract][Full Text] [Related]
16. Distinct roles of the mTOR components Rictor and Raptor in MO7e megakaryocytic cells.
Fuhler GM; Tyl MR; Olthof SG; Lyndsay Drayer A; Blom N; Vellenga E
Eur J Haematol; 2009 Sep; 83(3):235-45. PubMed ID: 19341427
[TBL] [Abstract][Full Text] [Related]
17. mTOR phosphorylated at S2448 binds to raptor and rictor.
Rosner M; Siegel N; Valli A; Fuchs C; Hengstschläger M
Amino Acids; 2010 Jan; 38(1):223-8. PubMed ID: 19145465
[TBL] [Abstract][Full Text] [Related]
18. Steady-state kinetic and inhibition studies of the mammalian target of rapamycin (mTOR) kinase domain and mTOR complexes.
Tao Z; Barker J; Shi SD; Gehring M; Sun S
Biochemistry; 2010 Oct; 49(39):8488-98. PubMed ID: 20804212
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 inhibitors suppress meningioma growth in mouse models.
Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes.
Ding F; Zhang X; Li X; Zhang Y; Li B; Ding J
PLoS One; 2014; 9(11):e112972. PubMed ID: 25393730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
